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Purpose: To evaluate the safety of Systane® Lubricant Eye Drops in relieving the symptoms 
of dry eye following laser-assisted in situ keratomileusis (LASIK) surgery.
Methods: This was a randomized, double-masked, single-center, placebo-controlled, 
contralateral eye study of 30 patients undergoing LASIK surgery. The mean age of patients was 
42.4 ± 10.7 years, and the mean spherical equivalent was −3.29 (range, +1.75 to −7.38). Patients’ 
right and left eyes were randomized to receive either Systane® or placebo – a preserved, 
thimerosal-free saline solution – beginning from the day of surgery and ending 30 days following 
surgery. Outcome measures included tear ﬁ  lm break up time (TFBUT), visual acuity, degree of 
corneal and conjunctival staining, and treatment-related adverse events.
Results: Preoperatively, placebo-treated eyes had statistically signiﬁ  cantly higher sum corneal 
staining score than Systane®-treated eyes (p = 0.0464); however, the difference was clinically 
insigniﬁ  cant (p = 0.27). Two weeks post operatively, the average TFBUT in the Systane®-treated 
eyes was 1.23 seconds longer than that of the placebo-treated eyes (p = 0.028). All other 
evaluated variables were comparable between the two treatments. No adverse events were 
reported in the study.
Conclusion: Systane® Lubricant Eye Drops are safe for use following LASIK surgery to relieve 
the discomfort symptoms of dry eye associated with the procedure.
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Introduction
Laser-assisted in situ keratomileusis (LASIK) is an effective procedure used to correct 
refractive errors. It affords patients a predictably fast and painless recovery of vision. 
To date, one of the major complications of LASIK surgery is persistent or temporary 
dry eye-like symptoms or the exacerbation of pre-existing dry eye conditions (Toda 
et al 2001). In healthy eyes, the tear ﬁ  lm supports and maintains the ocular surface. 
When tear production is needed, sensation from the ocular surface stimulates the brain, 
which sends secretomotor nerve impulses to the lacrimal glands to produce tears. 
In dry eyes, however, an abnormal or decreased tear ﬁ  lm causes irritation of the ocular 
surface, resulting in the release of cytokines that disrupt the neural arc. This disruption 
leads to interruption of secretomotor nerve impulses, neurogenic inﬂ  ammation of the 
lacrimal gland, activation of T-cells, and secretion of cytokines into tears that further 
inﬂ  ame the ocular surface and reduce normal tear production (Salib et al 2006). It is 
believed that severing the corneal nerves during LASIK surgery may interrupt the 
neural feedback loop to the lacrimal glands as well (Stern et al 1998; Patel et al 2001; 
Donnenfeld et al 2004).
Dry eye is a complex disease of inadequate lubrication of the ocular surface. 
It has a multifactorial etiology governed by various underlying conditions and Clinical Ophthalmology 2008:2(4) 974
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environmental factors. Although there are many contributing 
factors, ocular dryness is predominantly due to either aqueous 
deﬁ  ciency or to excessive evaporation of the tear ﬁ  lm. Patients 
may complain of symptoms of dry eye in the presence or 
absence of signs. Moreover, dry eye may be diagnosed based 
only on the signs observed by a healthcare professional or 
by an administered questionnaire such as the Ocular Surface 
Disease Index (OSDI). Dry eye is a highly prevalent disease 
and has the potential to cause functional impairment and a 
reduced quality of life (Foulks 2007). The tear ﬁ  lm contains 
a mixture of lipid, aqueous, and mucin layers in an interactive 
hydrated mucin gel pattern. Lipids are present not only on the 
surface of the tear ﬁ  lm, but also throughout the gel in asso-
ciation with proteins (Foulks 2005). It is generally accepted 
that the tear ﬁ  lm in dry eye patients is unstable and incapable 
of maintaining the protective qualities that are necessary for 
its structure and function. This instability causes patients to 
experience the discomfort symptoms associated with dry eye, 
such as burning, stinging, grittiness, foreign body sensation, 
tearing, ocular fatigue, and dryness (Terry 2001).
The mainstay therapy of dry eye is tear ﬁ  lm correction and 
improvement, which is achieved with topically administered 
lubricant eye drops. Relief from these drops essentially is 
transient due to low retention time on the ocular surface. 
Systane® Lubricant Eye Drops (Alcon Laboratories, Inc., Fort 
Worth, TX, USA) contains polyethylene glycol 400 (0.4%) 
and propylene glycol (0.3%) demulcents with the polymer 
hydroxypropyl guar (HP-Guar) as a gelling agent, and is pre-
served with POLYQUAD® 0.001% (polidronium chloride). 
Systane® is also available as a unit-dose, preservative-free 
preparation. In the bottle, Systane® consists of a loosely cross-
linked meshwork created by covalent interactions between 
borate and HP-Guar. When exposed to the higher pH (pH 7.5) 
of the ocular surface and tears (Yamada et al 1997), the 
HP-Guar forms a reversible cross-link with borate, culminating 
in a gel-matrix with sheer thinning viscoelastic and bioadhesive 
properties. The gel-matrix is designed to promote retention of 
the active demulcents, thereby protecting the ocular surface 
(Hartstein et al 2005; Gifford et al 2006).
The purpose of this study was to evaluate the safety of 
Systane® as compared with marketed saline (placebo) for 




Thirty (30) adults, regardless of gender or race, undergoing 
bilateral LASIK surgery, were enrolled in the study. 
All subjects signed an informed consent form before the 
beginning of the study. An institutional review board 
approved the study, and all testing was conducted in 
accordance with the board’s guidelines.
Inclusion and exclusion criteria
Study subjects were taken from a standard group of typical 
candidates for LASIK surgery, including patients over 
18 years of age and post-menopausal women, with a healthy 
ocular status and a preoperative refractive anisometropia 
of less than one diopter (1 D) between eyes. Prior to being 
approached for the study, all patients had expressed a desire 
for bilateral LASIK surgery, had a pre-operative evaluation 
(screening visit; Visit 1) indicating healthy ocular status, and 
had an established date for surgery. Other considerations 
for inclusion included the ability and willingness to appear 
at all in-ofﬁ  ce visits and to follow instructions. Women of 
childbearing potential were included in the study if they 
met all the following conditions: were not breast-feeding, 
had negative urine pregnancy test at the screening visit, 
agreed to undertake urine pregnancy test at the end of the 
study, were not planning to become pregnant during the 
course of the study, and agreed to use adequate birth control 
methods for the duration of the study. Subjects who did 
not wear soft contact lenses or rigid gas permeable lenses 
3 days and 3 weeks, respectively, prior to screening visit, 
and were willing to discontinue contact lens wear for the 
duration of the study were also included. Subjects were 
also included if they were willing and able to discontinue 
the use of all topical ocular medications and abstain from 
systemic medications known to cause ocular dryness for at 
least 2 weeks prior to LASIK surgery and throughout the 
duration of the study.
Patients were excluded from the study if they had had 
intraocular surgery, ocular trauma, active rosacea in either eye 
3 months prior to the screening visit, or had used RESTASIS® 
eye drops 30 days prior to the screening visit. Evidence of 
active intraocular inﬂ  ammation, chronic or recurrent uveitis 
or other inﬂ  ammatory eye disease in either eye, end stage 
salivary or lacrimal gland dysfunction, hepatitis-C or HIV 
infection, or graft versus host disease were also considered 
exclusion criteria. Other exclusion criteria included: dry eye 
due to Stevens-Johnson syndrome, Riley-Day syndrome, 
sarcoidosis, leukemia, severe meibomian gland dysfunction 
requiring treatment, active chemical burns, or nerve paresis; 
history of radiation therapy to the head above the angle of 
the jaw; and eyelid surface abnormalities that affect eyelid 
function.Clinical Ophthalmology 2008:2(4) 975
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Study medications and dose regimen
Test article: Systane® Lubricant Eye Drops.
Placebo: Sensitive Eyes® saline solution (Bausch and Lomb, 
Rochester, NY, USA).
Patients self-administered medication – 1 to 2 drops in 
each eye 2 times daily (bid) – beginning at the day of surgery 
(Day 0) and ending 30 days following LASIK surgery 
(Day 30). Patients were allowed to use the study medications 
every 30 minutes as needed immediately following LASIK 
surgery until bedtime the evening of surgery, and as rescue 
medication if necessary during the course of the study. Since 
the study was contralateral, patients were instructed to use 
the rescue medication only in the eye requiring additional 
medication, using the medication assigned for that eye. 
Furthermore, patients were required to document how much 
and how often rescue medication was used.
Study visits
The study consisted of 5 visits carried out in an approximately 
5-week period. Patients underwent eligibility screening and 
ocular surface evaluation on Visit 1 (Day −7 ± 2). Visit 
2 (Day 0) was the day of surgery on which the ocular surface 
was re-evaluated prior to surgery. Follow-up visits were Visit 
3 (Day 1), Visit 4 (Day 14 ± 3), and Visit 5 (Day 30 ± 7). 
Patients exited the study on Visit 5.
Each study visit included medical and medication 
history; overall dry eye and discomfort questions; dry eye 
post-LASIK questionnaire; uncorrected and best corrected 
visual acuity (VA) measurements (on Visit 3, only uncor-
rected VA was measured); and type, time, and frequency 
of rescue medication used (except on Visit 1). A thorough, 
slit-lamp biomicroscope examination was conducted on all 
study visits to examine and record any abnormalities in the 
cornea, conjunctiva, eyelids/eyelashes, anterior chamber, iris, 
and lens. Measurement of tear ﬁ  lm break up time (TFBUT), 
un-anesthetized Schirmer test, slit-lamp examination, sodium 
ﬂ  uorescein corneal staining, and lissamine green conjunc-
tival staining were conducted on all study visits except on 
Visit 3.
Study design
This was a prospective, randomized, double-masked, 
placebo-controlled, single-center, contralateral eye study. 
At the screening visit (Visit 1), subjects’ demographic 
information was recorded along with current/prior use of 
medications, lubricant eye drops, and ocular pathologies. 
Medications considered necessary to maintaining subjects’ 
health were used at the discretion of the investigator. Eyes of 
subjects satisfying the inclusion criteria were randomized to 
receive Systane® in one eye and placebo in the contralateral 
eye following LASIK surgery. To ensure proper masking of 
patients, medical personnel, and the examining investigators 
regarding the study medications, the test article and placebo 
were supplied as a pre-numbered kit containing two 15-mL 
bottles with sterile closures and masked labeling. To decrease 
the risk of cross-placement of drops, the masked medication 
labels were marked with a large “R” for the right eye, and 
“L” for the left eye.
To evaluate tear clearance rate and break up time, 
5 μL of 2% preservative-free sodium ﬂ  uorescein (Alcon 
Laboratories, Inc.) were instilled into the inferior conjunc-
tival cul-de-sac of each eye to measure the time taken from 
the blink until the ﬁ  rst dark spots or streaks appeared within 
the ﬂ  uorescein enhanced tear ﬁ  lm. The test was repeated 
3 times, and the score was the average of the 3 consecu-
tive measurements. To ensure the accuracy of the TFBUT 
tests, the tests were assessed by the same examiner at all 
visits using the same slit-lamp. Schirmer tests were carried 
out according to the Atlas of Primary Eyecare Procedures 
(Casser et al 1997).
Corneal staining was conducted 3 to 4 minutes after the 
TFBUT measurements. The type (severity) of staining was 
assessed for each of   the 5 regions of the cornea (central, 
inferior, temporal, superior, and nasal) (Figure 1). The type 
of staining was graded using the following grading scale: 0 
= normal–no staining, 1 = mild–superﬁ  cial stippling micro-
punctate staining, 2 = moderate–macropunctate staining 
with some coalescent areas, 3 = severe–numerous coales-
cent macropunctate areas and/or patches. The scores of the 
5 regions were summed to obtain the total area of staining 
score, with a minimum staining score of 0 and a maximum 
score of 15 for each eye.
To stain the conjunctiva, an Eppendorf ® pipette was used 
to instill 5 μL of 1% preservative-free lissamine green drops 
in each eye. The severity of staining was assessed for the 
6 regions of the conjunctiva, and the degree of staining was 
recorded separately for the 3 portions of the temporal conjunc-
tiva and the 3 portions of the nasal conjunctiva. The severity 
of conjunctival staining was graded using a scale ranging 
from 0 (best) to 3 (worst), with a minimum staining score of 
0 and a maximum score of 18 for each eye (Figure 2).
Uncorrected and best-corrected VA (UCVA and BCVA) 
testing preceded any examination requiring administration of 
eye drops to anesthetize or dilate the eye, or any examination 
requiring contact with the eye. ETDRS chart was used and 
the VA was calculated as a logMAR score.Clinical Ophthalmology 2008:2(4) 976
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Surgical procedure
All patients underwent bilateral simultaneous LASIK 
surgery performed by an experienced LASIK surgeon (DD). 
All ﬂ  aps were created with the 60 kHz IntraLase femtosec-
ond laser (Advanced Medical Optics, Irvine, CA, USA) with 
a planned ﬂ  ap diameter of 8.5 mm and an intended mean 
ﬂ  ap thickness between 100 and 110 μm. The Allegretto 
Wavelight excimer laser was used in 25 patients. The 
remaining 5 patients received wavefront-guided treatment 
using the Alcon LADAR4000 (Alcon Laboratories, Inc.) 
because of signiﬁ  cant preoperative higher order aberra-
tions. Standard postoperative medications including a 
fourth-generation ﬂ  uoroquinolone anti-inﬂ  ammatory eye 
drops (1 drop 4 times daily) and ﬂ  uorometholone (FML) 
steroid eye drops (1 drop 4 times daily) were prescribed to 
all patients. Oral pain medications were prescribed at the 
surgeon’s discretion.
Statistical analysis
Descriptive statistics were performed for all variables: aver-
age, standard deviation (SD), mean, and minimum/maximum 
value for continuous variables. Pearson’s Chi-square was 
chosen for categorical outcomes, and paired t-test was chosen 
for between-treatment comparisons of numeric outcomes 
with a bilateral signiﬁ  cance level of 5%.
Results
Demographics
Thirty (30) patients were enrolled and successfully completed 
all aspects of the study. The mean age of subjects was 
42.4 ± 10.7 years (range, 19 to 60); 16 patients (53%) were 
female.
Tear ﬁ  lm break up time (TFBUT)
TFBUT values were statistically comparable between 
the Systane®-treated and placebo-treated eyes throughout 
the study except on Visit 4 (Day 14) where the mean TFBUT 
in the Systane®-treated eyes was 1.23 seconds longer than 
that of the placebo-treated eyes (p = 0.028) (Table 1).
Schirmer tests
Before the initiation of the treatment, the mean Schirmer scores 
averaged 19.9 and 20.6 for Systane®- and placebo-treated eyes, 
respectively. There were no signiﬁ  cant differences in Schirmer 
scores between the two treatment groups following treatment 
(average 22.0 and 22.3, respectively).
C C
OD OS
Degree of Staining Region Degree of Staining
0 . . . . 1 . . . .2 . . . . 3  0 . . . . 1 . . . .2 . . . . 3 
0 . . . . 1 . . . .2 . . . . 3  0 . . . . 1 . . . .2 . . . . 3 
0 . . . . 1 . . . .2 . . . . 3  0 . . . . 1 . . . .2 . . . . 3 
0 . . . . 1 . . . .2 . . . . 3  0 . . . . 1 . . . .2 . . . . 3 
0 . . . . 1 . . . .2 . . . . 3 
C - Central 
S - Superior 
T - Temporal 
N - Nasal 




Grade 0 = Normal No staining
Grade 1 = Mild Superficial stippling micropunctate staining
Grade 2 = Moderate Macropunctate staining with some coalescent areas
Grade 3 = Severe Numerous coalescent macropunctate areas and/or patches
Figure 1 Corneal regions and staining grades.Clinical Ophthalmology 2008:2(4) 977
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Ocular surface evaluation
There were no signiﬁ  cant differences measured by sodium 
ﬂ  uoroscein or lissamine green staining between eyes treated 
with either Systane® or placebo except on Visit 1 where 
placebo-treated eyes had statistically higher sum corneal 
staining score than Systane®-treated eyes (p = 0.046); how-
ever, the difference was clinically insigniﬁ  cant (p = 0.27).
Safety
No eye in either treatment group showed an increase in 
corneal, conjunctival, lens, anterior chamber, or iris slit-lamp 
ﬁ  ndings. Intraocular pressure measurements at Visits 1 and 
5 showed no signiﬁ  cant differences between treatment groups 
or as compared to baseline values. Likewise, there were no 
treatment-related adverse events or serious adverse events 
in this study. These results demonstrate that Systane® used 
2 times daily after LASIK surgery was safe and well tolerated 
by refractive surgery patients.
Discussion
In this study, the safety of Systane® Lubricant Eye drops 
following LASIK surgery was assessed in 30 patients 
undergoing bilateral surgery. Systane® was administered 
into one randomly assigned eye, and the contralateral eye 
served as control, receiving Sensitive Eyes® preserved saline 
solution. The results show that Systane® was safe to use 
following LASIK surgery, including the day of surgery, 
to relieve the postoperative dry eye symptoms induced by 
LASIK surgery. It is important to note that the Systane® 
formulation used in this study was the Polyquad-preserved 
formulation not the preservative-free formulation. There 
were no differences between Systane®- and placebo-
treated eyes in vital staining, UCVA, BCVA, and TFBUT. 
However, 14 days post operatively, the mean TFBUT in the 
Systane®-treated eyes was 1.23 seconds longer than that of 
the placebo-treated eyes. These data add more evidence and 
weight to the earlier conclusions drawn by Christensen et al 
regarding the overall safety proﬁ  le of Systane® (Christensen 
et al 2004).
The ocular surface microenvironment is made up of 
surface epithelial cells, the glycocalyx, and the tear ﬁ  lm. 
A breakdown in any one of these components can lead to 
disruption of the tear ﬁ  lm and damage to epithelial cells, 
















Figure 2 Conjunctival regions and staining grades.
Table 1 Comparison of tear ﬁ  lm break-up time (TFBUT) between Systane®-treated eyes and placebo-treated eyes
# of Systane® Placebo
Variable eyes Mean (SD) Range Mean (SD) Range p valuea
Visit 1 (screening) 30 7.42 (3.68) 2.67–14.00 7.80 (3.26) 3.00–12.67 0.2757
Visit 2 (Day 0) 30 6.94 (3.66) 2.33–21.00 7.63 (3.58) 2.33–19.33 0.0703
Visit 3 (Day 1) 30 5.17 (2.04) 1.33–9.00 5.57 (2.67) 1.00–12.33 0.3535
Visit 4 (Day 14 ± 3) 30 6.40 (3.10) 2.33–14.00 5.17 (2.37) 2.00–11.67 0.0281
Visit 5 (Day 30 ± 7) 30 6.33 (3.18) 2.00–15.00 6.28 (2.81) 2.00–13.33 0.8662
ap values of the paired t-test for comparisons between the two treatments using contralateral eyes as controls.Clinical Ophthalmology 2008:2(4) 978
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symptoms (Ousler et al 2002). While the damaged cells 
are being replaced, the ocular surface remains unpro-
tected. Although the cause of dry eye after LASIK has 
not been completely clariﬁ  ed, severing the corneal nerves 
during LASIK surgery during the creation of the ﬂ  ap, 
as well as laser ablation, have been suspected to play an 
important role (Linna et al 1998; Donnenfeld et al 2004); 
therefore, intervention to help protect the ocular surface 
environment during the healing process potentially would 
be beneﬁ  cial.
While new therapeutic strategies based on the 
pathophysiology of dry eye are currently being developed, 
lubricant eye drops continue to be the mainstay care of 
dry eye. The major goal of these products is to restore 
the ocular surface integrity in an attempt to reduce the 
symptoms associated with dry eye. Lubricant eye drops 
provide a physical protective barrier that works in con-
junction with blinking to help spread the tear ﬁ  lm over 
the ocular surface (Versura et al 2008). A protected ocular 
surface, in fact, will exist as long as the tear ﬁ  lm is stable 
and when the TFBUT matches or exceeds the inter-blink 
interval (IBI). Conversely, when the TFBUT is less than 
the IBI, the corneal surface will be unprotected for a period 
of time between blinks, inducing ocular dryness (Ouslar 
et al 2007). Systane® works by binding to the hydrophobic 
exposed areas of the epithelial cells and attaching a 
protective HP-Guar tear-gel matrix that helps restore the 
ocular surface and increases TFBUT (Korb et al 2002; 
Korb et al 2005).
In summary, LASIK surgery induces tear-deﬁ  cient 
dry eye and exacerbates preexisting dry eye by disturbing 
corneal innervations. Candidates for surgery should 
be screened properly so that preexisting dry eye is 
detected, and all candidates should be warned against 
the possible development of LASIK-induced dry eye. 
Administration of Systane® starting from the day of 
surgery and insertion of punctual plugs are recommended 
to reduce discomfort during the symptomatic postoperative 
period.
This study had two limitations. Systane®-treated eyes may 
have beneﬁ  ted from a preoperative treatment period and 
perhaps from a longer than 1 month postoperative treatment 
period. An extended postoperative treatment period may 
have evidenced more differences between the two treatment 
groups and provided additional power to the safety data. 
Likewise, additional signiﬁ  cant differences between the 
treatment groups may have been found with a larger patient 
population.
Conclusion
Systane® Lubricant Eye drops are safe for use following 
LASIK surgery to relieve the dry eye discomfort symptoms 
induced or exacerbated by this procedure.
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